Shorter Regimen Of High-Dose Rifampicin Fails To Demonstrate Noninferiority Compared To Six Month Regimen For Treatment Of Pulmonary TB, Study Finds
August 31, 2023
MedPage Today (8/30, Ingram) reports, “Shorter high-dose rifampicin regimens proved safe for treating pulmonary tuberculosis (TB), but failed to demonstrate noninferiority compared with the standard 6-month regimen, a phase III trial found.” Nonetheless,...